Brainstorm Cell Therapeutics Inc.
BCLI
$0.642
-$0.0032-0.50%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.45M | -11.09M | -11.62M | -14.23M | -12.75M |
| Total Depreciation and Amortization | 215.00K | 228.00K | 240.00K | 253.00K | 259.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.08M | 768.00K | 221.00K | 6.86M | 2.86M |
| Change in Net Operating Assets | 676.00K | 2.43M | 2.07M | -4.21M | -4.82M |
| Cash from Operations | -9.48M | -7.66M | -9.09M | -11.33M | -14.44M |
| Capital Expenditure | -- | -- | -- | -18.00K | -18.00K |
| Sale of Property, Plant, and Equipment | 12.00K | 12.00K | 12.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 214.00K | 202.00K |
| Cash from Investing | 12.00K | 12.00K | 12.00K | 196.00K | 184.00K |
| Total Debt Issued | 900.00K | 900.00K | -- | -- | -- |
| Total Debt Repaid | -1.10M | -- | -- | -- | -- |
| Issuance of Common Stock | 5.09M | 6.11M | 7.97M | 10.26M | 17.36M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.95M | 1.50M | -- | -- | -- |
| Cash from Financing | 6.85M | 8.51M | 7.97M | 10.26M | 17.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.62M | 865.00K | -1.11M | -873.00K | 3.10M |